A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.
Back
Exploring Targeted Therapy for T-Cell Lymphoma After CAR T-Cell Therapy
Samir Parekh, MBBS, details a case study on targeted therapy for CAR-positive T-cell lymphoma after anti-BCMA CAR T-cell therapy.
Exploring Targeted Therapy for T-Cell Lymphoma After CAR T-Cell Therapy
Episodes
All
All
Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.
Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
The OncFive: Top Oncology Articles for the Week of 8/9
5